Altum Sequencing Wins Best Product Award at The Ventures Spain 2026
- Altum Sequencing
- Jun 26
- 2 min read
Second recognition in two weeks for the Madrid-based precision oncology company, honoured for its molecular monitoring technology
Altum Sequencing has been recognized as "Best Product" during The Ventures Spain 2026, an event that brought together founders, investors, and ecosystem leaders in Madrid — marking the company's second recognition in just two weeks.
Representing Altum's Product Vision
Representing Altum Sequencing at the event, Isabel Espejo Díaz, PhD, shared the company's product vision with the investor and startup ecosystem: scaling advanced molecular technologies to make cancer monitoring more precise, accessible, and impactful for patients and healthcare systems.
The award recognizes Altum Sequencing's work developing ctDNA-based liquid biopsy technology, designed to support continuous, precise monitoring of cancer through molecular data — an approach that resonated with the investor and startup community gathered at the event.
A Growing Ecosystem of Recognition
Altum Sequencing extends its thanks to the The Ventures team and to co-organizers Geoffrey Rolin Jacquemyns, Liam Coyle, and Ana Olga Chirpan for bringing this edition to life and creating a meeting point for founders, investors, and ecosystem leaders. The company also congratulates fellow category winners pisopro, ANIMAL SURFING, and Sabia, along with all finalists and startups that took the stage.
Momentum Building
This Best Product award follows closely on the heels of Altum Sequencing's recognition by healthstart madri+d, reflecting a period of sustained momentum for the company. Together, these recognitions highlight both the clinical relevance and the market potential of Altum's technology, as it continues to scale its molecular monitoring platform and expand its presence across the healthcare innovation and investment ecosystem.
As Altum Sequencing continues its journey from hospital-born research to a growing precision oncology company, these back-to-back recognitions reinforce its position as an emerging leader in liquid biopsy-based cancer monitoring — technology built in Europe, with the ambition to impact patients worldwide.
Altum Sequencing is a precision oncology company based in Madrid, Spain, developing ctDNA-based liquid biopsy technology for cancer monitoring. Spun off from Hospital Universitario 12 de Octubre, the company's platform supports minimal residual disease detection and longitudinal treatment monitoring across a range of oncology indications.
Comments